Page 490 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

474 PART 6 ■ Neoplastic Disorders

Kr lovics R, et l. A g in-o - unction ut tion o JAK2 in yeloproli -
COMPANION RES OURCES
er tive isor ers, N Engl J Med, 352(17):1779–1790, 2005.

Klippel S, et l. Bioche ic l ch r cteriz tion o PV-1, novel he to-
http://thepoint.lww.co / urgeon6e
poietic cell sur ce receptor, which is overexpresse in polycythe-

E ch stu ent is encour ge to ccess n use the Web- i rubr ver , Blood, 100(7):2441–2448, 2002.

b se co p nion resources evelope or this ch pter. L rson RA. Is there best KI or chronic ph se CML? Hematology Am

Here, you will f n ition l le rning tools to incre se Soc Hematol Educ Program, 2015:250–256.

your un erst n ing o the concepts n clinic l pplic - Lee SJ, et l. I p ct o prior i tinib esyl te on the outco e o he -

tions o the ch pter. topoietic cell tr nspl nt tion or chronic yeloi leuke i , Blood,
112(8):3500–3507, 2008.

Levine RL, Gillil n G. Myeloproli er tive isor ers, Blood,
112(6):2190–2198, 2008.

BIBLIOGRAPHY M rtinelli G, et l. New tyrosine kin se inhibitors in chronic yeloi

leuke i , Haematologica, 90(4):534–541, 2005.

Bowers GR (e .). Polycythe i rubr ver , CDH Oncol, 7(7):1–6, 2003. M sc renh s J. Looking orw r : novel ther peutic ppro ches in
C pbell PJ, Green AR. T e yeloproli er tive isor ers, N Engl J Med, chronic n v nce ph ses o yelof brosis, Hematology Am Soc

355(23):2452–2466, 2006. Hematol Educ Program, 2015:329–336.

Cl rk M. Chronic yelo onocytic leuke i tr ns or ing into cute Mu precht S, et l. I tinib esyl te selectively i p irs exp nsion o
yelogenous leuke i , Lab Med, 40(1):19–21, 2009. e ory cytotoxic cells without ecting the control o pri ry

Conley CL. Polycythe i ver , JAMA, 263(18):2481–2483, 1990. vir l in ections, Blood, 108(10):3406–3413, 2006.

Cris n D, C rr ER. BCR/ bl gene re rr nge ent in chronic yeloge- O’Brien SG, et l. I tinib co p re with inter eron n low- ose

nous leuke i n cute leuke i s, Lab Med, 23(11):730–735, 1992. cyt r bine or newly i gnose chronic-ph se chronic yeloi

D o K , yner JW. Wh t’s i erent bout typic l CML n chronic leuke i , N Engl J Med, 348(11):994–1004, 2003.
neutrophilic leuke i ? Hematology Am Soc Hematol Educ Program, P l n ri F, et l. Chronic yeloi leuke i in bl st crisis tre te with

2015:264–270. i tinib 600 g: outco e o the p tients live er 6-ye r ollow-

Deininger MW. Molecul r onitoring in CML n the prospects or up, Haematologica, 93(12):1792, 2008.
tre t ent- ree re issions, Hematology Am Soc Hematol Educ Peggs K, M ckinnon S. I tinib esyl te—the new gol st n-

Program, 2015:257–262. r or tre t ent o chronic yeloi leuke i , N Engl J Med,

Drucker BJ. r nsl tion o the Phil elphi chro oso e into ther py 348(11):1048–1050, 2003.

or CML, Blood, 112(13):4808–4817, 2008. Quintás-C r A, Cortes J. Molecul r biology o bcr- bl1-positive

Eg n JM. rgeting ste -cells in chronic yeloi leuke i with chronic yeloi leuke i , Blood, 113(80):1619–1630, 2009.
PPAR- lph gonist, N Engl J Med, 373(20):1973–1975, 2015. R i D, Geyer HL. M n ge ent o sy pto s in polycythe i ver

F b rius A, et l. Dyn ics o cytogenetic berr tions in Phil elphi n essenti l thro bocythe i p tients, Hematology Am Soc

chro oso e positive n neg tive he topoiesis uring s tinib Hematol Educ Program, 2015:340–348.
ther py o chronic yeloi leuke i p tients er i tinib ilure, R n olph . JAK2: the next BCR/ABL ong the yeloproli er tive

Haematologica, 92(6):834–837, 2007. isor ers (MPN)? ACLS oday, 22(5):5–11, 2008.

F erl S, et l. T e biology o chronic yeloi leuke i , N Engl J Med, Rowe JM. Closing the g p in CML, Blood, 109(6):2271, 2007.

341(3):164–172, 1999. S glio G. Me suring olecul r response in CML: proble s n signif -

Fouc r K. CSP 2015 Short Course, Leukemia Classif cation 2016: What, c nce. In: Imatinib—Impact on CML Management and Beyond, 8th
When, “Who,” S cr ento, CA: C li orni Society o P thologists, EHA Congress, Lyon, Fr nce, 2003.

2015. Sch ich M, et l. Prognosis o cute yeloi leuke i p tients up to

Hehl nn R, S ussele S. re t ent o chronic yeloi leuke i in 60 ye rs o ge exhibiting triso y 8 within non-co plex k ryo-
bl st crisis, Haematologica, 93(12):1765–1768, 2008. type: in ivi u l p tient t -b se et - n lysis o the Ger n

Hochh us A. Molecul r response n resist nce to I tinib (Glivec®. cute yeloi leuke i intergroup, Haematologica, 92(6):
)
In: Education Book o the 8th EHA Congress, Lyon, Fr nce, 763–770, 2007.

2003:15–20. Schi er CA. BCR-ABL tyrosine kin se inhibitors or chronic yelog-

Hochh us A. Perspectives on n ging resist nce in CML. In: enous leuke i , N Engl J Med, 357(3):258–265, 2007.
Imatinib—Impact on CML Management and Beyond, 8th EHA Schw rtz R. A olecul r st r in the w rs g inst c ncer, N Engl J Med,

Congress, Lyon, Fr nce, 2003. 347(7):462–463, 2002.

K nt rji n HM, et l. Long-ter surviv l benef t n i prove co - Scott LM, et l. JAK2 exon 12 ut tions in polycythe i ver n i io-
plete cytogenetic n olecul r response r tes with i tinib p thic erythrocytosis, N Engl J Med, 356(5):459–468, 2007.

esyl te in Phil elphi chro oso e-positive chronic-ph se S yth MJ. I tinib esyl te—uncovering st tr ck to ptive

chronic yeloi leuke i er ilure o inter eron-α, Blood, i unity, N Engl J Med, 354(21):2282–2284, 2006.

104(7):1979–1988, 2006. Stu rt BJ, Vier AJ. Polycythe i ver , Am Fam Physician, 69:

K nt rji n H, et l. Nilotinib in i tinib-resist nt CML n Phil elphi 2139–2144, 2146, 2004.
chro oso e-positive ALL, N Engl J Med, 354(24):2542–2551, lp z M. D s tinib in i tinib-resist nt Phil elphi chro oso e-

2006. positive leuke i s, N Engl J Med, 354(24):2531–2540, 2006.